NSE · INDOCO · Pharmaceuticals
Indoco Remedies Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹409 Cr with net profit ₹82 Cr — a 20.13% net margin, versus -5.15% the period before.
Shareholding
As of 2026-06-30
- Promoter58.86%
- Public22.18%
- FII1.27%
- DII17.68%
32,457 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.96× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #47 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,44,093 Cr | 35.15 | 5.31 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,17,007 Cr | 23.96 | 4.32 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,832 Cr | 31.25 | 3.25 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,09,397 Cr | 100.03 | 20.64 | 16.77% | 15.04% |
| Mankind Pharma Limited | ₹1,02,890 Cr | 48.23 | 6.31 | 11.74% | 13.86% |
| Dr Reddys Laboratories Ltd. | ₹1,01,255 Cr | 31.43 | 2.66 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,843 Cr | 25.88 | 2.58 | 9.25% | 10.7% |
| Lupin Limited | ₹96,877 Cr | 16.26 | 4.32 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹69,879 Cr | 22.39 | 6.65 | 28.08% | 10.22% |
| Biocon Ltd. | ₹64,463 Cr | 88.29 | 1.87 | 1.14% | 2.89% |
| Indoco Remedies Ltd.(this company) | ₹2,361 Cr | — | 2.51 | -10.13% | 30.79% |
AI analysis
AI-generated · google/gemini-2.5-flashIndoco Remedies Ltd., listed as INDOCO, has a market capitalization of Rs 2257 Cr. The company reported a revenue of Rs 1670.37 Cr with a profit margin of -5.31%. Its debt-to-equity ratio stands at 0.78.
Positives
- +No promoter shares are pledged, with promoter pledge at 0% as of June 30, 2026.
- +The dividend yield is 8%, indicating a return to shareholders.
Negatives
- −Revenue growth decreased by -8.4%.
- −The profit margin is negative at -5.31%.
- −The company reported a negative return on equity (ROE) of -10.13%.
- −Earnings per share (EPS) for March 2025 was negative at -8.45.
- −No quarterly results have been disclosed since March 2026.
Financial Performance
Indoco Remedies Ltd. reported an annual revenue of Rs 1670.37 Cr, marking a revenue growth decrease of -8.4%. The company experienced a net profit of -73.7369 Cr for the period ending March 2025. Quarterly, revenue was Rs 475.61 Cr in March 2026, with a net profit of -21.64 Cr. The EBITDA for the same quarter was 17.18.
Profitability & Returns
The company's profitability metrics show a negative profit margin of -5.31%. Return on equity (ROE) is -10.13%, and return on capital employed (ROCE) is 0.77%. The earnings per share (EPS) for the period ending March 2025 was -8.45.
Balance Sheet
The book value per share for Indoco Remedies Ltd. is Rs 101.76. The company has a debt-to-equity ratio of 0.78, indicating the proportion of debt used to finance its assets relative to shareholder equity.
Ownership & Pledges
Promoter holding in Indoco Remedies Ltd. stands at 58.8636% as of June 30, 2026. Public shareholding is 22.1824%. There are no reported promoter pledges.
Data as of — price: 2026-09-23 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.